GLP-1 Obesity support app
Holistic support through a patient’s weight-loss Journey
We are developing a GLP-1 obesity support app that encourages adherence and sustainable lifestyle changes for patients and provides pharma companies with invaluable real-world data.
We understand that consistent and correct administration of a GLP-1 drug combined with lifestyle changes are key to sustainable weight-loss. We also know that there is pressure from regulators, payers, and healthcare providers to demonstrate patient outcomes and value. Our app concept addresses these challenges and is ready for customization to the individual requirements of a pharma company.
Empowering Patients to manage their weight-loss journey
“I don’t know where and how to start (again).”
We heard this many times when interviewing patients beginning or restarting their weight-loss journey. The experience can be overwhelming and challenging. It is complex to navigate all the information online and hard to know what to trust.
Combining GLP-1 therapy with a support app helps cut through the noise, providing clear, actionable guidance and support. This may improve patient care experience, adherence, and contribute to improved long-term outcomes.
Your Advantages
Support for patient adherence
Supports long-term GLP-1 drug adherence with guidance, reminders, side-effect tracking and education to help reduce overwhelm and anxiety.
Weight-loss assistance
Provides guidance on life-style changes with goal-setting and interventions to boost motivation and aid positive habit formation.
Insights from RWE
Provides data on treatment journey and experience to support HCPs and demonstrate long-term outcomes to regulators and payors.
GLP-1 Management to support long-term adherence
Consistent, ongoing use of a prescribed GLP-1 therapy is crucial to weight-loss success, but up to 64% of GLP-1 patients discontinue therapy within the first year*. Anxiety and inexperience with self-injection, unrealistic expectations, and side-effects can reduce adherence and lead to discontinuation of treatment.
Our concept for a support app could help patients with:
- Learning content on expectation management and relapse
- Timely reminders to administer and record injections
- Guidance on injector handling
- Patient tracking of administration
- Side-effect tracking, education and mitigation strategies
*EMJ European medical journal (2024): High Discontinuation Rates of GLP-1 Agonists in Patients Who Are Obese
Motivational holistic weight-loss assistance
Integratedmulti-modal support with clear routines could help patients reduce overwhelm, boost motivation and also aid positive habit formation. Features could include:
Realistic, achievable goal-setting with clear routines for positive habit formation, movement, hydration, nutrition, and mental health
Personalized meal & exercise plans tailored to the GLP-1 medication, patient´s goals, lifestyle, and progress
Interventions based on CBT to keep up motivation, help prevent relapses, and avoid emotional eating
Integration of data from leading health apps
Real-world evidence of patient outcomes
In addition to supporting patients in achieving sustainable weight loss, a GLP-1 support app could provide pharma companies with structured, clinically meaningful data on treatment journeys and experience. This data could support healthcare professionals in optimizing therapy provision and may help demonstrate long-term outcomes to regulators and payers.
Potential aggregated data:
Medication intake
Weight loss
Side effects
Challenges and success strategies
Accompanying movement
- Diet
Deep understanding of needs in the obesity space
Our expert team has conducted in-depth research and engaged with patients and healthcare professionals to better understand the real-world challenges of obesity. As one of the leading global suppliers of pen injectors for GLP-1 therapies and diabetes care, we also understand the needs of our pharma customers in this field.
We have applied this knowledge and experience to devise our concept for a GLP-1 obesity support app. The app will be further developed, customized and branded with a pharma company to meet their specific requirements.
As a first step towards supporting people with their weight loss journey, GewichtsKompass.de* is a digital tool that helps people in Germany navigate their path to treatment. This privacy-first guide enables those struggling with obesity to better understand their individual situation and explore evidence-based treatment options.
*Sensile Medical, a Gerresheimer company, is the entity responsible for this product.
Global, multidisciplinary pharma expertise
We develop smart, connected solutions that seamlessly integrate with your drug delivery systems – enhancing patient engagement, monitoring adherence, and generating real-world insights.
Our multidisciplinary team spans experts in pharma, human-centered design, software development, and medical sciences. They collaborate closely with our partners to co-create digital health solutions that truly respond to identified needs and challenges.
By combining Gerresheimer’s proven drug delivery expertise with digital innovation, we help you to deliver more than medication: we enable a connected care experience that brings value to you, your patients, and healthcare providers.
Get in touch with us now to explore how we can partner to develop impactful, patient-centered solutions in obesity care.
Contact the expert
Sarah Wieske
Digital Solution Lead
